<DOC>
	<DOC>NCT01401244</DOC>
	<brief_summary>This trial is conducted in United States of America (USA). The aim of this trial is to examine the bioequivalence of Norditropin速 versus Genotropin速 in healthy adult volunteers.</brief_summary>
	<brief_title>Bioequivalence of Two Somatropin Products (Norditropin速 Versus Genotropin速) in Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Prader-Willi Syndrome</mesh_term>
	<mesh_term>Dwarfism</mesh_term>
	<mesh_term>Growth Disorders</mesh_term>
	<criteria>Body mass index (BMI) 18.027.0 kg/m^2 (both inclusive) Considered generally healthy upon completion of medical history, physical examination, vital signs, screening laboratory results, and electrocardiogram (ECG), as judged by the Investigator (trial physician) The receipt of any investigational medicinal product within 1 month prior to this trial Current or previous treatment with growth hormone or IGFI (insulinlike growth factorI) Female of childbearing potential who is pregnant, breastfeeding or intends to become pregnant or is not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice) for the duration of the trial Known presence or history of malignancy Diabetes mellitus Use of pharmacologic doses of glucocorticoids Use of anabolic steroids History of drug or alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>